Abstract P353: New Evidence on the Association of Physical Activity and Chronic Kidney Disease: ORISCAV-LUX Study
Background: Evidence on stages of renal impairment and related risk factors in Luxembourg adults is lacking. This study aimed to assess the prevalence of chronic kidney disease (CKD) and identify potential correlates among general population in Luxembourg, using the recent definition suggested by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines.
Methods: Analyses were based on data from 1361 adult participants aged 18-69 years, enrolled in the Observation of Cardiovascular Risk Factors in Luxembourg (ORISCAV-LUX) study, 2007-2008. Descriptive and multivariable logistic regression analyses were performed to identify demographic, socio-economic, clinical and behavioral factors associated with CKD, defined as single estimated glomerular filtration rate (eGFR) measure <60 ml/min/1.73m2 and/or urinary albumin creatinine ratio (ACR)>30mg/g.
Results: Overall, 6.3% had CKD, including 4.4% and 0.7% presented with moderate and severe macroalbuminuria respectively, and 0.1% had kidney failure (eGFR<15 mL/min/1.73 m2). CKD risk increased significantly with age; the odds ratio increased more than two folds among subjects aged 50-69 years, with no sex-specific difference. CKD was higher among subjects with primary education. Hypertension and diabetes were associated with more than 3-fold and 4-fold higher risk of CKD [adjusted odd ratio (95%CI): 3.11 (1.76, 5.52); P<0.001] and [adjusted odd ratio (95%CI): 4.69 (2.35, 9.36), P<0.001] respectively. Increased physical activity measured as total MET-hour/week was independently associated with a lower odd of CKD (P=0.035).
Conclusion: The prevalence estimate of CKD in Luxembourg may represent a neglected public health issue, stressing the benefit of early detection of CKD, particularly in subjects with hypertension, diabetes, lipid disorders and obesity. Promoting physical activity among these high-risk subjects should be considered to prevent CKD. These measures altogether could defray costs related to eventual complications and decrease risk of associated cardiovascular events.
Author Disclosures: A. Alkerwi: None. N. Sauvageot: None. S. Stranges: None. C. Delagardelle: None. J. Beissel: None.
- © 2017 by American Heart Association, Inc.